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This was a randomised controlled study, carried out in a single centre. The median duration of the follow-up was 24 months. Loss to follow-up was not reported (except for 11 who crossed-over to the SURG group and two who required adjunctive percutaneous transluminal angioplasty). All the grafts were upper extremity expanded polytetrafluoroethylene grafts. All the procedures were performed in an endovascular operating suite with fistulography. Inadequate information was given regarding the randomisation procedure.
Analysis of effectiveness
The principle used in the analysis of effectiveness was both intention to treat and treatment completers. The health outcomes were procedure time, procedure-related complications, cumulative primary and assisted primary patency, time to graft rethrombosis, and the number of cross-over patients. The patency outcomes were calculated using the Kaplan Meier life-table method. With the exception of age, the study groups were comparable in terms of preoperative features.
Effectiveness results
The average procedure time was 99 minutes in the SURG group versus 113 minutes in the ENDO group, (p=0.12). There were no procedure-related complications which required treatment in either group. At a median follow-up time of 24 months, there was no difference in primary or assisted primary patency between groups, which averaged 6 (SURG) and 7 (ENDO) months, (NS). Eleven patients in the ENDO group crossed over to surgical revision as compared with two patients in the SURG group who required adjunctive percutaneous transluminal angioplasty, (p=0.005). The analysis per protocol had similar findings in terms of patency rate.
Clinical conclusions
The authors concluded that although long-term success is limited with both approaches, the patency rates for patients who undergo treatment with endovascular therapy are comparable with the rates for those who undergo surgical treatment.
Measure of benefits used in the economic analysis
No summary benefit measure was identified in the economic analysis, and only separate clinical outcomes were reported.
Direct costs
Costs were not discounted due to the short time frame of the cost analysis. Some quantities were reported separately from the costs Cost items were not reported separately. Cost analysis covered the procedure-related costs (including complications) which included operating room time and supply costs but excluded professional fees. The perspective adopted in the cost analysis was not explicitly specified and the price year was not given.
